All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
An expert panel hosted by
Customizing first-line BTK inhibitors for CLL
with Gilles Salles, Paolo Ghia, and Francesc Bosch
Wednesday, October 23, 2024
18:30-19:30 BST
This independent educational activity is supported by Pharmacyclics LLC, an AbbVie Company and Janssen Biotech. All content is developed independently by the faculty. The funder is allowed no influence on the content of this activity.
The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
On 14 June 2019, at the 24th European Hematology Association Congress in Amsterdam, Steven Le Gouill, from Chu de Nantes, Nantes, FR, presented results of the LYMA-101 phase II trial. This study found that obinutuzumab plus DHAP (O-DHAP) followed by autologous stem cell transplantation (ASCT) plus obinutuzumab maintenance, provided a high minimal residual disease (MRD) response rate in untreated patients with mantle cell lymphoma (MCL).
The primary objective of the study was the MRD negativity rate after four cycles of O-DHAP and was assessed by IGH clonospecific testing or bcl1-JH PCR quantification. Secondary objectives included overall response rate (ORR), complete response (CR), progression-free survival (PFS), overall survival (OS), incidence of stem cell collection failure, duration of MRD response and tolerability.
Discontinuations |
Safety set (n = 85) |
---|---|
All discontinuations |
25 |
AEs |
13 |
Progression |
3 |
Secondary malignancy (e.g. squamous cell carcinoma tonsil, MDS) |
3 |
Physician decision |
2 |
Death |
2 |
Major protocol violation |
1 |
Voluntary discontinuation/consent withdrawal |
1 |
Period |
Safety set (n = 85) |
---|---|
Before treatment |
1 |
Before ASCT |
4 |
Before maintenance |
11 |
During maintenance |
9 |
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Your opinion matters
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox